Relief Therapeutics Holding AG (RLFTF)

[go_wamu]

My dear Vanilla!
I've been ignoring you since November. Lately I've been reading your posts again because its content is important. Therefor I’ve „unignored“ you again !
..... but if you mention:

NEURORX shall own all right, title and interest in and to all Results, the Feasibility Study Documentation and all inventions, discoveries, innovations and know-how and including all rights to patent any of the foregoing that is an extension of or improvement to NEURORX's Background IPR or that otherwise relates to the NEURORX Materials

.... then you might have forgotten that there is an agreement (contract) between RELIEF and NEURORX that has to be kept. While it is true that NEURORX provided all of the above services, they were paid for it as a result of the agreement. Under this contract they were obliged to do their job. It therefore makes no sense to discuss who is entitled/responsible for what, if you dont know the contract.
Now, on the last statement made by NEUROX:

The issues raised by Relief Therapeutics in its release dated April 19, 2021 have no bearing on NeuroRx’s ability or commitment to deliver a safe, effective, and stable lifesaving drug on a worldwide basis. However, NeuroRx was obligated to disclose Relief’s nonpayment of development costs required under the signed collaboration [...]

IMO there are doubts as to whether NEURORX was not using these "unpaid costs" deliberately as an excuse to overturn the cooperation agreement, also in order to escape funding from RELIEF. RELIEF would be well advised to settle these $ 4M quickly, possibly to check in retrospect whether this requirement is correct.
If I'm correctly informed, the cooperation agreement was concluded on September 23, 2020, i.e. 1 1/2 months after the first success with Aviptadil became known. The small private company NEURORX certainly knew the potential of this cooperation agreement and must have known also that the main burden of developing the RLF-100/Zyesami is in their responsibility, while RELIEF is responsible for financing the project.
IMO, I am also sure that the goal of all efforts was to achieve approval by the FDA and thus also phase II of the cooperation agreement, profit-sharing in marketing.
..... and now, shortly before reaching this goal, they are at odds with each other and they only will lose or win together. It's actually up to both of them.
The main thing should not be forgotten: The Aviptadil patent owns RELIEF.